SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Summary

This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.

Timeline

Start

2024-02-01

Primary completion

2025-06-30

Completion

2026-06-30

Drugs

Indications